Drug Trial Radar · NCT04652076
GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
238
Actual
Start
Dec 14, 2020
Primary completion
Oct 30, 2025
Study completion Nov 16, 2026
Sponsor
- Lead sponsor
- NETRIS PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC; Centre Leon Berard
- First posted
- Dec 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with pembrolizumab and/or chemotherapies in patients with advanced/metastatic gynecological cancers (2 types: endometrial carcinoma and cervix carcinoma).
Conditions
- Endometrial Carcinoma
- Cervix Carcinoma
Interventions
NP137Drug
Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
PembrolizumabDrug
Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
PaclitaxelDrug
Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
CarboplatinDrug
Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT occurrenceTime frame: Safety run in Period: At the end of Cycle 2 (each cycle is 21 days) for the first 6 to 12 patients per arm
- Overall response Rate (ORR)Time frame: At 3 months of treatement and then every 12 weeks, up to 2 years
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
CHRU BESANCON - Hopital Jean Minjoz
Besançon, France
Institut Bergonié
Bordeaux, France
Centre François Baclesse
Caen, France
Centre Georges François Leclerc
Dijon, France
Primary Completion Date
Lille, France
Centre Léon Bérard
Lyon, France
Primary Completion Date
Marseille, France
ICM - Val d'Aurelle
Montpellier, France
Insitut de cancérologie de l'ouest
Nantes, France
Hopital de la Croix Saint Simon
Paris, France
Institut Curie (Site Saint Cloud)
Paris, France
Institut Gustave Roussy
Paris, France
Aphp Cochin
Paris, France
Centre Eugène Marquis
Rennes, France
Institut claudius Regaud
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.